Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of BP11 (Omalizumab Biosimilar) Compared To EU-Omalizumab And US-Omalizumab

Authors
Category Primary study
ConferenceAMERICAN ACADEMY OF ALLERGY, ASTHMA & IMMUNOLOGY
Year 2026
This article has no abstract
Epistemonikos ID: d138020d918caeb1f160998a9c7f5b78620280e6
First added on: Feb 14, 2026